Edition:
United States

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

7.00USD
23 Apr 2018
Change (% chg)

$0.15 (+2.19%)
Prev Close
$6.85
Open
$6.85
Day's High
$7.60
Day's Low
$6.83
Volume
190,788
Avg. Vol
123,237
52-wk High
$7.60
52-wk Low
$0.91

Chart for

About

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $445.71
Shares Outstanding(Mil.): 65.07
Dividend: --
Yield (%): --

Financials

  CASI.OQ Industry Sector
P/E (TTM): -- 185.04 32.78
EPS (TTM): -0.17 -- --
ROI: -32.42 -0.74 13.21
ROE: -36.31 -2.80 15.01

BRIEF-CASI Pharma Says Advisory Committee to Review Evomela Between April 25-26

* CASI PHARMACEUTICALS - RECEIPT OF LETTER FROM CENTER FOR DRUG EVALUATION FOR INJECTION SCHEDULED FOR REVIEW BY ADVISORY COMMITTEE

Apr 05 2018

BRIEF-CASI Pharmaceuticals Q4 Loss Per Share $0.08

* CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 29 2018

BRIEF-CASI Pharmaceuticals Announces $50 Million Private Placement

* CASI PHARMACEUTICALS ANNOUNCES $50 MILLION PRIVATE PLACEMENT TO PREPARE COMPANY FOR COMMERCIALIZATION IN CHINA

Mar 20 2018

BRIEF-Casi Pharmaceuticals Enters Into A Common Stock Sales Agreement With H.C. Wainwright & Co

* CASI PHARMACEUTICALS INC SAYS ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO LLC - SEC FILING

Feb 23 2018

BRIEF-CASI Pharma Board Approves Appointment Of Wei-Wu He As Executive Chairman

* CASI PHARMACEUTICALS - ON FEB 7, BOARD APPROVED APPOINTMENT OF WEI-WU HE, CURRENT CHAIRMAN OF BOARD, AS EXECUTIVE CHAIRMAN - SEC FILING Source text: (http://bit.ly/2EUtR7g) Further company coverage:

Feb 09 2018

BRIEF-Casi Pharmaceuticals Files For Stock Shelf Of Upto $100 Million

* CASI PHARMACEUTICALS INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING Source text: [http://bit.ly/2zaieHQ] Further company coverage:

Dec 13 2017

BRIEF-Casi pharmaceuticals Q3 loss per share $0.03

* Casi Pharmaceuticals reports third quarter 2017 financial results

Nov 14 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.80 +0.17
Johnson & Johnson (JNJ.N) $126.83 +0.17
Novartis AG (NOVN.S) CHF76.04 -0.04
Merck & Co., Inc. (MRK.N) $60.25 +1.42
Roche Holding Ltd. (ROG.S) CHF217.60 +1.95
Roche Holding Ltd. (RO.S) CHF221.40 +1.40
Sanofi SA (SASY.PA) €65.71 +0.43
Amgen, Inc. (AMGN.OQ) $174.66 +3.10
Gilead Sciences, Inc. (GILD.OQ) $74.01 +0.31
AEterna Zentaris Inc. (AEZS.TO) $2.04 +0.12

Earnings vs. Estimates